Physician profile
Christopher C Jeffries
NPI 1306003819
$3,878.92
in general payments reported to CMS, 2019-2025
17 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $130 · 2021: $304 · 2022: $601 · 2023: $926 · 2024: $488 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765 · Long Term Medical Supply Or Device Loan: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.12 |
| Long Term Medical Supply Or Device Loan | $537.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $1,189.00 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Merz North America, INC. | $952.66 | 2019-2023 | Xeomin |
| Integra Lifesciences Corporation | $623.29 | 2022-2025 | Durasorb Monofilament Mesh, Integra, Surgimend |
| Abbvie INC. | $264.35 | 2023-2025 | |
| Convatec INC. | $193.81 | 2023-2024 | |
| Allergan, INC. | $121.63 | 2021-2022 | |
| Osiris Therapeutics INC. | $89.32 | 2019 | |
| Kls-Martin L.P. | $88.34 | 2022 | |
| Revance Therapeutics, INC. | $71.08 | 2024 | Daxxify |
| Kerecis Limited | $57.01 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $56.21 | 2022-2024 | |
| Stryker Corporation | $39.12 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $37.88 | 2023-2024 | |
| Motiva USA, LLC | $35.46 | 2025 | |
| Tepha INC | $27.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $20.49 | 2022 | |
| Bard Peripheral Vascular, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jeffries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.